The amyloid-beta pathway in Alzheimer's disease: a plain language summary
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Hampel, Harald | - |
dc.contributor.author | Hu, Yan | - |
dc.contributor.author | Hardy, John | - |
dc.contributor.author | Blennow, Kaj | - |
dc.contributor.author | Chen, Christopher | - |
dc.contributor.author | Perry, George | - |
dc.contributor.author | Kim, Seung Hyun | - |
dc.contributor.author | Villemagne, Victor L. | - |
dc.contributor.author | Aisen, Paul | - |
dc.contributor.author | Vendruscolo, Michele | - |
dc.contributor.author | Iwatsubo, Takeshi | - |
dc.contributor.author | Masters, Colin L. | - |
dc.contributor.author | Cho, Min | - |
dc.contributor.author | Lannfelt, Lars | - |
dc.contributor.author | Cummings, Jeffrey L. | - |
dc.contributor.author | Vergallo, Andrea | - |
dc.date.accessioned | 2023-08-01T06:30:01Z | - |
dc.date.available | 2023-08-01T06:30:01Z | - |
dc.date.created | 2023-05-03 | - |
dc.date.issued | 2023-06 | - |
dc.identifier.issn | 1758-2024 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/188366 | - |
dc.description.abstract | What is this summary about? This plain language summary of an article published in Molecular Psychiatry, reviews the evidence supporting the role of the amyloid-b (Ab) pathway and its dysregulation in Alzheimer's disease (AD), and highlights the rationale for drugs targeting the A beta pathway in the early stages of the disease. Why is this important? A beta is a protein fragment (or peptide) that exists in several forms distinguished by their size, shape/structure, degree of solubility and disease relevance. The accumulation of A beta plaques is a hallmark of AD. However, smaller, soluble aggregates of A beta - including Ab protofibrils - also play a role in the disease. Because A beta-related disease mechanisms are complex, the diagnosis, treatment and management of AD should be reflective of and guided by up-to-date scientific knowledge and research findings in this area. This article describes the A beta protein and its role in AD, summarizing the evidence showing that altered A beta clearance from the brain may lead to the imbalance, toxic buildup and misfolding of the protein - triggering a cascade of cellular, molecular and systematic events that ultimately lead to AD. What are the key takeaways? The physiological balance of brain A beta levels in the context of AD is complex. Despite many unanswered questions, mounting evidence indicates that A beta has a central role in driving AD progression. A better understanding of the A beta pathway biology will help identify the best therapeutic targets for AD and inform treatment approaches. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | FUTURE MEDICINE LTD | - |
dc.title | The amyloid-beta pathway in Alzheimer's disease: a plain language summary | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Seung Hyun | - |
dc.identifier.doi | 10.2217/nmt-2022-0037 | - |
dc.identifier.scopusid | 2-s2.0-85164336027 | - |
dc.identifier.wosid | 000960864600001 | - |
dc.identifier.bibliographicCitation | NEURODEGENERATIVE DISEASE MANAGEMENT, v.13, no.3, pp.141 - 149 | - |
dc.relation.isPartOf | NEURODEGENERATIVE DISEASE MANAGEMENT | - |
dc.citation.title | NEURODEGENERATIVE DISEASE MANAGEMENT | - |
dc.citation.volume | 13 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 141 | - |
dc.citation.endPage | 149 | - |
dc.type.rims | ART | - |
dc.type.docType | Article; Early Access | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Neurosciences & Neurology | - |
dc.relation.journalWebOfScienceCategory | Clinical Neurology | - |
dc.subject.keywordPlus | amyloid beta protein | - |
dc.subject.keywordPlus | apolipoprotein E4 | - |
dc.subject.keywordPlus | biological marker | - |
dc.subject.keywordPlus | tau protein | - |
dc.subject.keywordPlus | Alzheimer disease | - |
dc.subject.keywordPlus | brain interstitial fluid | - |
dc.subject.keywordPlus | cerebrospinal fluid | - |
dc.subject.keywordPlus | disease exacerbation | - |
dc.subject.keywordPlus | fibril | - |
dc.subject.keywordPlus | human | - |
dc.subject.keywordPlus | late onset disorder | - |
dc.subject.keywordPlus | nonhuman | - |
dc.subject.keywordPlus | pathology | - |
dc.subject.keywordPlus | protein aggregation | - |
dc.subject.keywordPlus | protein targeting | - |
dc.subject.keywordPlus | Review | - |
dc.subject.keywordAuthor | Alzheimer&apos | - |
dc.subject.keywordAuthor | s disease | - |
dc.subject.keywordAuthor | amyloid beta | - |
dc.subject.keywordAuthor | A beta plaques | - |
dc.subject.keywordAuthor | biomarkers | - |
dc.subject.keywordAuthor | dementia | - |
dc.subject.keywordAuthor | protofibrils | - |
dc.subject.keywordAuthor | tau | - |
dc.identifier.url | https://www.futuremedicine.com/doi/10.2217/nmt-2022-0037 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.